Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-28T11:50:24.706Z Has data issue: false hasContentIssue false

Daytime/nighttime levels of serum IL-33 in schizophrenia at hospital admission and before discharge

Published online by Cambridge University Press:  19 July 2023

J. J. Tascon-Cervera*
Affiliation:
Psychiatry, Universitary Hospital of Canary Island
A. Morera-Fumero
Affiliation:
Departamento de Medicina Interna, Dermatología y Psiquiatría, Facultad de Ciencias de la Salud
P. Abreu-Gonzalez
Affiliation:
Ciencias Medicas Basicas: Unidad de Fisiologia, Facultad de Ciencias de la Salud, Universidad de La Laguna, San Cristóbal de La Laguna
E. Diaz-Mesa
Affiliation:
Psychiatry, Universitary Hospital of Canary Island
M. R. Cejas-Mendez
Affiliation:
Psychiatry, Universitary Hospital of Canary Island
S. Yelmo-Cruz
Affiliation:
Psychiatry, Universitary Hospital of Canary Island
L. Fernandez-Lopez
Affiliation:
Departamento de Medicina Interna, Dermatología y Psiquiatría, Facultad de Ciencias de la Salud
A. Marcos-Rodrigo
Affiliation:
Psychiatry, Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

It has been reported an inflammatory state in schizophrenia, with altered levels of some cytokines (Zhou et al. Cytokine 2021; 141:155441). Recent publications have shown the importance of IL- 33, a member of the IL-1 cytokine family which acts as an alarmin (Han et al. Neurosci Bull 2011; 27, 351-357). The role of this cytokine as a biomarker has been investigated in schizophrenia (Koricanac et al. Front Psychiatry 2022; 13, 925757). However, results are controversial. Some studies have not found significant associations between IL-33 and chronic schizophrenia (Campos-Carli et al. Compr Psychiatry 2017; 74 96-101), while other papers have reported increased levels (Kozlowska et. al. J Psychiatr Res. 2021; 138 380-387). In all these studies, levels of IL-33 were measured in a single daily measure, so that it has not been studied if IL-33 has changes during hospitalization.

Objectives

To study the serum level of IL-33 at 12:00 and 00:00 hours in schizophrenia patients at admission and before hospital discharge.

Methods

Fifteen inpatients with diagnosis of paranoid schizophrenia according to ICD-10 criteria were studied. Patients were hospitalized at the University Hospital of the Canary Islands psychiatric ward because of an acute relapse. A total of four blood samples were taken from each patient: at 12:00 and 00:00 hours the day after admission and at 12:00 and 00:00 hours the day before discharge. Serum IL-33 levels were measured by ELISA techniques. Daytime and nighttime IL-33 serum levels at admission and discharge were compared using a non-parametric Wilcoxon signed-rank test.

Results

In table 1 the results of the comparison of IL-33 at admission and discharge are presented. There is a significant reduction of IL-33 levels at 00:00 h. at discharge in comparison with the IL-33 levels at 00:00 h. at admission (p=0.028). No other statistically significant differences were observed.

SerumIL-33AdmissionMean±sdDischargeMean±sdZPvalue
12:00 h.191.0±348.7247.0±378.2-0.1660.868
00:00 h.218.8±370.3153.6±275.7-2.2030.028

Conclusions

The decrease of serum IL-33 at 00:00 at discharge compared to the 00:00 IL-33 serum level at admission points to the utility of this biomarker as a surrogate of brain inflammation.

Disclosure of Interest

None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.